ESMO 2020 | Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate 577

Elizabeth C. Smyth, MD, Cambridge University Hospitals NHS Foundation Trust, discusses the results of the CheckMate 577 (NCT02743494) trial. The trial investigated adjuvant nivolumab in esophageal cancer or gastroesophageal junction cancer patients following chemoradiation therapy. The primary endpoint, disease-free survival, was met. Patients in the treatment group had a disease-free survival double of the placebo group. However, whether the treatment is equivalent between adenocarcinomas and squamous cell carcinomas is up for debate. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).